$ITNS - newsletters out - ITNS Is Our New Blockbuster Sub Penny Biotech Pick
ITNS - The New Blockbuster Biotech play that looks to Break Records by Monday. We are known for picking Biotech plays and our history speaks loud and clear for Mega Home run biotech plays. We are pounding the table tonight on ITNS and wanted issue this URGENT: Bullish Full Coverage Report and Alert on it before it makes its Mega Breakout Move/Run.
ITNS is our New Sub Penny Biotech pick at .0037 cents. If you recall our last Biotech pick, BMSN, was a blockbuster hit and ran from .0024 to .0165 (588% run) short term.
ITNS looks to make a major move here short term. We believe ITNS is a blockbuster hit down here at .0037 cents (Sub penny levels) and we are hearing some major things are in the pipeline for ITNS. The company has been releasing some Recent Mega News, is trading way undervalued near its 52 week low and the BUZZ is starting to rapidly increase for this Biotech play.
ITNS (Itonis Pharmaceuticals, a division of Itonis, Inc.) is headed by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. He and his team plan to use the same methodologies to revolutionize the treatments of several other common ailments and other chronic diseases. For more information on Itonis, Inc., please visit www.itonisholdings.com.
Vip Members, ITNS is opportunity knocking at dirt cheap levels with Screaming Upside Potential.
Here are some Highlights as to why we feel ITNS could be the Next Blockbuster Biotech play trading at Way Undervalued levels:
ITNS and Charles Hensley, Ph.D., the inventor of the Zicam® Cold Remedy, and the founding President of Itonis Pharmaceuticals, are pleased to announce their second product offering since the formation of Itonis Pharmaceuticals as a division of Itonis, Inc. The new product offering, details of which will be revealed over the coming weeks, is an anti-HIV preparation that is based entirely on natural compounds.
Dr. Hensley commented, "Along with the preparation for the anti-nausea product we recently announced, we have been perfecting our anti-HIV technology. One attractive aspect of this technology is that it targets the viral entry step that gives it a broad application base. It is very important to protect this intellectual property before disseminating the specifics of the compound. We expect the process of protecting this valuable technology to begin over the coming weeks."
ITNS recently announced that it will begin organizing clinical trials for its over-the-counter, systemically active anti-nausea preparation delivered via a nasal and/or sublingual spray for the alleviation of mild to moderate nausea. It also expects to begin organizing clinical trials for this new anti-HIV technology over the coming weeks.
While the size of the market for anti-nausea related drugs and preparations is not exactly known, ITNS estimates it to be well in excess of $1 BB annually. There have been relatively few innovations within this product category over the past few years and the company believes the market is ripe for a new type of anti-nausea preparation to be available over-the-counter.
ITNS previously announced the selection of its U.S.-based manufacturer. Under the leadership of Dr. Hensley, the Company is on target to begin full production of its anti-nausea spray with product sales set to begin by Summer 2013. "We are very excited that our new anti-nausea product will reach consumers just in time for summer vacation travels. It is always a proud moment when a product cycle matures from the design phase and advances to the point of actual consumer use. Please stay tuned for further production updates in the coming weeks and months ahead," says Dr. Hensley, President of Itonis Pharmaceuticals, and Mark Cheung, CEO of Itonis, Inc.
Dr. Hensley commented, "Many millions of Americans will travel this year and approximately 33% of the population is susceptible to motion sickness, even in mild circumstances. The specter of becoming nauseous on a trip continues to be a big issue for leisure travelers. Our initial marketing objective is to introduce our anti-nausea products to the traveling population by partnering with airlines, cruise ship lines, hotels and internet travel sights as well as other professionals in the travel industry.
ITNS plans to announce other aspects of the overall marketing plan for this product in near future.
Vip Members: ITNS, Our New Sub Penny Biotech Play, looks to be the Next Blockbuster hit in the Micro-Cap markets and we feel this is Massive News or the Horizon here short term. ITNS is way undervalued and trading dirt cheap so make sure to act fast on this hidden biotech gem.
